Publication:
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Simple item page
dc.contributor.authorRondy, Marc
dc.contributor.authorKissling, Esther
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorGherasim, Alin Manuel
dc.contributor.authorPebody, Richard
dc.contributor.authorTrebbien, Ramona
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorMcMenamin, Jim
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE/I-MOVE+ group
dc.contributor.authorDelgado-Sanz, Concepcion
dc.contributor.authorOliva Dominguez, Jesus Angel
dc.contributor.authorCasas Flecha, Inmaculada
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.date.accessioned2020-01-30T09:32:12Z
dc.date.available2020-01-30T09:32:12Z
dc.date.issued2018
dc.description.abstractBetween September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years. All study teams are very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams, regional epidemiologists who have contributed to the studies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website www.gisaid.orges_ES
dc.format.number9es_ES
dc.format.volume23es_ES
dc.identifier.citationEuro Surveill. 2018 Mar;23(9):18-00086.es_ES
dc.identifier.doi10.2807/1560-7917.ES.2018.23.9.18-00086es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.issn1560-7917es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.identifier.pubmedID29510782es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8992
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/634446es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/ECDC/2014/026es_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología (CNE)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEuropees_ES
dc.subjectCase control studyes_ES
dc.subjectInfluenzaes_ES
dc.subjectInfluenza vaccinationes_ES
dc.subjectInfluenza vaccine effectivenesses_ES
dc.subjectMulticentre studyes_ES
dc.subject.meshAdolescentes_ES
dc.subject.meshAdultes_ES
dc.subject.meshAgedes_ES
dc.subject.meshChildes_ES
dc.subject.meshChild, Preschooles_ES
dc.subject.meshEuropees_ES
dc.subject.meshEuropean Uniones_ES
dc.subject.meshFemalees_ES
dc.subject.meshHumanses_ES
dc.subject.meshInfantes_ES
dc.subject.meshInfant, Newbornes_ES
dc.subject.meshInfluenza A Virus, H1N1 Subtypees_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtypees_ES
dc.subject.meshInfluenza B viruses_ES
dc.subject.meshInfluenza Vaccineses_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPandemicses_ES
dc.subject.meshTreatment Outcomees_ES
dc.subject.meshVaccinationes_ES
dc.subject.meshSeasonses_ES
dc.titleInterim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studieses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione264f82c-6c07-4aa5-9f71-45e555f6592b
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublicatione77e1f2d-b4e2-4ba5-a853-c2795850dcae
relation.isAuthorOfPublicatione89a616b-8c7b-43b9-b3df-2a44c45e0765
relation.isAuthorOfPublicatione5273a7c-5f8e-464e-bea8-d933a72965b7
relation.isAuthorOfPublicatione2df6e55-f1d3-423b-a72f-fd9a69cf5915
relation.isAuthorOfPublication.latestForDiscoverye264f82c-6c07-4aa5-9f71-45e555f6592b
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublication.latestForDiscovery78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Interim2017_18InfluenzaSeasonal_2018.pdf
Size:
533.4 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Epidemiología (CNE)
Centro Nacional de Microbiología (CNM)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)